EAM Investors’s Taysha Gene Therapies TSHA Stock Holding History

EAM Investors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-823,758	Closed	-$4.53M	–	376
2025 Q4	$4.53M	Buy	+823,758	New	+$4M	0.5%	87
2023 Q4	–	Sell	-335,390	Closed	-$1.06M	–	378
2023 Q3	$1.06M	Buy	+335,390	New	+$626K	0.2%	231

Other funds holding TSHA

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM Investors's TSHA Position: Q1 2026 in Review

EAM Investors sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 823,758 shares — an estimated $4.53M sold.

EAM Investors first reported a position in TSHA in Q3 2023 and held it in 2 quarters. The position peaked at $4.53M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

EAM Investors reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
EAM Investors sold 823,758 Taysha Gene Therapies shares in Q1 2026, an estimated $4.53M.
EAM Investors first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 2 quarters.
EAM Investors's Taysha Gene Therapies position peaked at $4.53M in Q4 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.